p16-INK4 polyclonal, anti-human, mouse, rat, dog, pig, chicken

Protein Family: Protein Kinases

Pathway and Disease: Cancers, Cell Growth and Death, Signaling Molecules and Interaction

Description:
The cyclin-dependent kinase 4 inhibitor A (CDK4I or p16-INK4) acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6 and by subsequently inhibiting their interaction with cyclins D and retinoblastoma protein phosphorylation. Defects in p16-INK4 are involved in tumor formation in a wide range of tissues. These defects cause cutaneous malignant melanoma 2 (CMM2), familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, melanoma-astrocytoma syndrome and Li-Fraumeni syndrome.

Alternate Names: Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, cyclin-dependent kinase inhibitor A, CDK4I, p16-INK4a, p16INK4A, p16-INK4, multiple tumor suppressor 1, MTS-1, CDKN2A, CDKN2, MTS1

Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500; IHC: 1:100-1:500

Accession No.: P42771

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the center region of human p16-INK4.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4, 25% glycerol, 1 mg/ml BSA with 0.09% sodium azide. Antibody was purified by Protein-A affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.

Product Citations:
[1] Chinzei N et al. 2015. Mol Med Rep. 11(3): 1601-8. PMID# 25376471.
[2] Jackson L et al. 2011. Cellular Immunology. 272(2): 200-213. PMID# 22078270.